M100700053 shivani kakria
52
Presentation On NOVARTIS (A PHARMACEUTICAL COMPANY) SHIVANI KAKRIA
-
Upload
shivanikakria -
Category
Business
-
view
2.177 -
download
0
description
marketing assignment on" NOVARTIS"
Transcript of M100700053 shivani kakria
Presentation On
NOVARTIS(A PHARMACEUTICAL
COMPANY)
SHIVANI KAKRIA
SLOGAN OF NOVARTIS
CARING AND CURING
MISSION
INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.
VISSION
HEALTHCARE THAT FOCUSES ON CREATING,DEVELOPING AND MANUFACTURING A WIDE RANGEOFCOMPETITIVELY DIFFERENTIATED PRODUCTSTHAT RESTORE,MAINTAIN AND IMPROVE THE HEALTH AND WELL-BEING OF CUSTOMERS.
HUMAN RESOURCE BUILDING OF NOVARTIS
IN BASEL.
KEY PEOPLE
CHAIRMAN : DANIEL VASELLA
CEO: JOSEPH JIMENEZ
REVENUE:US $44.27BILLION
NETINCOME:US$8.40BILLION
OPERATING INCOME:US $9.98
EMPLOYEES:99,830
SUBSIDIARIES:CIBAVISION,SANDOZ
NOVARTIS WINS TWO SCRIP AWARDS FOR
BEST OVERALL PIPELINEAND CORPORATE SOCIAL
RESPONSIBILITY.
SHARE ANALYSIS OF NOVARTIS
GROWTH IN VARIOUS PRODUCT CATEGORIES…..
EMERGING MARKETSOF NOVARTIS
oCHINA
oRUSSIA
oTURKEY
oSOUTH KOREA
oBRAZIL
oINDIA
EMERGING MARKKETS IN
PHARMACEUTICALS..
WE OFFER A BROAD RANGE OF HEALTHCARE SOLUTIONS THAT MEETSTHE EVOLVING AND UNMET NEEDS OF PATIENTS AND SOCITIESWORLDWIDE.
OUR MEDICINES AND VACCINES PROTECTED 930 MILLIONPEOPLE IN 2009.
STRONG FINANCIAL PERFORMANCE SHOWS OUR ABILITY TOTO FULFILL OUR PRIMARY MISSIONTO CARE AND CURE..
WHERE INTEGERITY AND HIGH ETHICAL STANDARDS REMAINSESSENTIAL TO OUR LONG TERM SUCCESS.
SOME IMP. FACTS
A PHARMACEUTICAL COMPANY
FOUNDED IN 1996,
HD.QT’S-BASEL AND SWITZERLAND.
RANKING 3 IN SALES AMONG WORLDWIDE INDUSTRY.
IS 6 T H LARGEST IN TERMS OF REVENUE. .
IS MEMBER OF EUROPEAN FEDERATION OFPHARMACEUTICAL INDUSTRIES
ANDASSOCIATION .
ABOUT COMPANY
NOVERTIS PRODUCTS
Issuer Amount(in millions) Coupon Maturity
Novartis Capital Corp. 2,000 1.900% 2013
Novartis Capital Corp. 2,000 4.125% 2014
Novartis Capital Corp. 2,000 2.900% 2015
Novartis SecuritiesInvestment Ltd. 3,000 5.125% 2019
Novartis Capital Corp. 1,000 4.400% 2020
USD FIXED INCOME SECURITIES
FINANCIAL DEVELOPMENTS IN
2009NET SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION.
PHARMACEUTICALS: RANKS AS ONE OF THE INDUSTRY FAST GROWING COMPANIES IN 2009 WITH NET SALES OF 8%(+12% IN LC) TO USD 28.5BILLION.
VACCINES AND DIAGNOSTICS:38%(39% IN LC) NET SALES INCCREASE TO USD 2.4 BILLION..
SANDOZ: NET SALES FALLS 1% TO USD 7.5 BILLION BUT RISE 5%LC AS NEGATIVE CURRENCY OVERSHADOWS OPERATIONAL GAINS FROM NEW LAUNCHES.
CONSUMER HEALTH:EXPAND MARKET SHARE IN ALL BUSINESS ECONOMIC ACTIVITIES WITH SALES OF USD 5.8 BILLION.
;
SOME OTHER FINANCIALDEVELOPMENTS
OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANSIONAND PRODUCTIVITY GAINS MORE DUE TO NEGATIVE IMPACT OF LOCAL CURRENCY.
NET INCOME:GROWS 4% TO USD 8.5 BILLION DUE TO RELATED FINANCIAL COST AND INCOME FROM ASSOCIATED COMPANIES.
BASIC EARNING PER SHARE:RISE FROM 3% TO 3.70,CORE EPS RISES FROM 8% TO USD 4.50.
DIVIDEND:INCREASES 3.7%
PRODUCTIVITY:EXCEEDING THE TARGET BY 0.7 BILLION.
WHAT TYPE OF BUSINESS WE ARE IN??
PHARMACEUTICAL
VACCINES AND DIAGNOSTICS
SANDOZ(GENERICS)
OVER THE COUNTER
ANIMAL HEALTH
CIBA VISION
Comtan- $420 M (2007)- Parkinson's disease Diovan- $5.0 B sales[25] (2007)- Hypertension Exjade- $357 M (2007) - Iron chelator Femara- $937 M (2007)- Breast cancer Gleevec- $3.1 B- for Chronic myeloid leukemia Lescol- $665 M (2007)- hypercholesterolemia Lotrel- $748 M (2007)- Hypertension Lucentis- $393 M (2007)- Age-related macular degeneration Ritalin- $375 M (2007) - AD/HD Exelon- $632 M (2007)- Alzheimer's disease Sandimmune and Neoral- $944 M (2007)- Organ transplantation Sandostatin - $1.0 B (2007) - Acromegaly Tegretol- $413 M (2007)- Epilepsy Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain. Tobramycin- $273 M (2007)- Cystic fibrosis Trileptal- $692 M (2007)- Epilepsy Voltaren- $747 M (2007)- anti-inflammatory Zometa- $1.3 B (2007)- Cancer complications Tofranil- - antidepressant
PHARMACEUTICALS
HEALTHCARE OTCBenefiberBuckley's cold and cough formulaBufferinComtrex cold and coughDenavir/VectavirDesenexDoan's pain reliefEx-LaxExcedrinFenistilGas-XHabitrolKeri skin careLamisil foot careLipactin Herpes symptomatic treatmentMaaloxNicotinellNo-doz
ANIMAL CAREPETS CARE
Interceptor (Milbemycin oxime), oral worm control productSentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control productDeramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogsCaps tar (Nitenpyram), oral tablet for flea controlMilbemax (Milbemycin oxime, Praziquantel), oral worm treatmentProgram (Lufenuron), oral tablet for flea control
LIVESTOCK
Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattleCLiK (Dicyclanil), blowfly control for sheepDenagard (Tiamulin)Fasinex (Triclabendazole)ViraShield
NET SALES BY REGION IN %
UNITED STATESASIA/AFRICA
0
10
20
30
40
50
60
PHARMACEUTICALVACCINES AND DIAGNOSTICSSANDOZCONSUMER HEALTH
OP-ERAT-ING IN-
COME
0
20
40
60
80
PHARMACEUTICALVACCINES AND DIAGNOSTICSSANDOZCONSUMER HEALTH
CORE OPERATING INCOME BY DIVISION
CORE OPERATING INCOME
BY DIVISION IN %
NET SALES BY DIVISION IN %
SALES
0
10
20
30
40
50
60
70
PHARMACEUTICAL
CONSUMER HEALTH
PHARMACEUTICALVACCINES AND DIAGNOSTICSSANDOZCONSUMER HEALTH
COMPETITORS IN INDIA
NAME OF THE COUNTRY
1. DR.REDDY’S LAB2. CIPLA3. PIRAMAL
HEALTHCARE4. GLAXO INDIA LTD.5. SUN
PHARMACEUTICAL
TOTAL REVENUE (IN USD BILLIONS) 1.5 1.28 0.84 0.43 0.42
COMPETITORS IN SWITZERLAND
NAME OF THE COUNTRY
1. HOFFMAN LA ROCHE
2.NYCOMED
TOTAL REVENUE (IN USD BILLIONS) 47.35
4.26
COMPETITORS IN GERMANY
NAME OF THE COUNTRY
1. BAYER
2. BOEHRINGER INGELHEIM
3. MERCK kGaA
TOTAL REVENUE (IN USD BILLIONS)
22.3
16.9
5.17
COMPETITORS IN JAPANNAME OF THE COUNTRY
1. TAKEDAPHARMACEUTICAL.
2. ASTELLAS PHARMA
3. DAIICHI SANKYO 9
4. EISAI
5. CHUGAI PHARMACEUTICAL .
TOTAL REVENUE (IN USD BILLIONS)
15.6
10.7
9
5.5
2.0
COMPETITORS IN USA
NAME OF THE COMPANY
1. JOHNSON AND JOHNSON
2. ABOTT LABORATORIES
3. MERC K AND CO.
4. ELI LILLY
5. BRISTOL MAYER SQUIBB
TOTAL REVENUE(IN USD BILLIONS )
61.90
30.76
27.43
21.84
18.81
COMPETITORS IN UK
NAMEOF THE COMPANY
TOTAL REVENUE (IN USD BILLIONS)
45.83
32.811. GlaxoSmithKline
2. AstraZeneca
2009 net sales - USD 7.5 billion
DIOVAN
CHEMICAL DATA
FORMULA:C24H29N5O3
MOL.MAS:435.519G/MOL
SMILES:eMolecules AND Pubchem
Pharmacokinetic dataBioavailability:25%
Protein binding:95%
Half life :6hours
Excretion:renal 30%,biliary70%
DIOVAN IS INDICATED
FOR THE TREATMENT OF
HIGH BLOOD PRESSURE,
HEART FAILURE ANDMYOCARDIAL INFARCTION.
FOR THE DIABETES PATIENTS
In patients with impaired glucose tolerance, valsartan may decrease the incidence of developing type 2 diabetes mellitus.
However, the absolute risk reduction is small (<1%/year) and diet + exercise or other drugs, maybe more protective. In the same
study, no reduction in the rate of cardiovascular events (including death) was shown. In other words, taking Valsartan didn't make the
patients live longer.
BRANDSIN US , VALSARTAN IS MARKETED UNDER TRADE MARK
DIOVAN.
IN PAKISTAN ,IT IS MARKETED UNDER TRADE MARK ANGIOTAN.
IN INDIA,IT IS MARKETED BY CIPLA UNDER TRADE MARK VALTAN AND BY TORRENT PHARMACEUTICALS UNDER NAME
VALZAAR.
SIDE EFFECTS OF DIOVAN
LEADS TO HEADACHE AND DIZZINESS.SENSTIVITY TO SUNLIGHT AND BRIGHT
ARTIFICIAL LIGHT.
THERE IS A CASE OF A STILLBIRTH IN WHICH VALSARTAN IS
IMPLICATED.
THANKS
